Open Access
Med Sci (Paris)
Volume 34, Number 11, Novembre 2018
Page(s) 910 - 913
Section Le Magazine
Published online 10 December 2018
  1. Ding L, Bailey MH, Porta-Pardo E, et al. Perspective on oncogenic processes at the end of the beginning of cancer genomics. Cell 2018 ; 173 : 305–320. [CrossRef] [PubMed] [Google Scholar]
  2. Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget 2017 ; 8 : 114371–114392. [PubMed] [Google Scholar]
  3. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 ; 369 : 29–36. [CrossRef] [PubMed] [Google Scholar]
  4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010 ; 376 : 687–697. [CrossRef] [PubMed] [Google Scholar]
  5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005 ; 5 : 341–354. [Google Scholar]
  6. Larbouret C, Gaborit N, Poul MA, et al. Le récepteur HER3 ou ERB3 - La face cachée de la planète ERB. Med Sci (Paris) 2015 ; 31 : 465–468. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018 ; 554 : 189–194. [CrossRef] [PubMed] [Google Scholar]
  8. Mainardi S, Mulero-Sánchez A, Prahallad A, et al. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nat Med 2018 ; 7 : 961–967. [Google Scholar]
  9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783–792. [Google Scholar]
  10. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015 ; 372 : 724–734. [Google Scholar]
  11. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012 ; 379 : 633–640. [CrossRef] [PubMed] [Google Scholar]
  12. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016 ; 17 : 738–746. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.